The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,774.50
Bid: 1,774.00
Ask: 1,774.50
Change: -3.50 (-0.20%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,793.50
Low: 1,766.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

INSIGHT-Currency drop hits Egypt's medicine supplies, angering public

Tue, 22nd Nov 2016 13:27

* Pharma companies halting imports of drugs after currencyfloat

* Govt unwilling to ease price controls, deepening shortages

* Companies say govt plan to subsidise key drugsinsufficient

* Black market springs up

By Arwa Gaballa and Eric Knecht

CAIRO, Nov 22 (Reuters) - Pharmacies across Egypt arerunning short of medicines, some of them life-savers, as aplunge in the value of the Egyptian pound coupled with strictgovernment price caps has made scores of products unprofitableto produce or import.

The shortages include some cancer treatments as well asbasic items like insulin, tetanus shots and contraceptive pills.

Unable to raise prices above levels set by the HealthMinistry but now paying roughly twice as much to import drugs oractive ingredients, pharmaceutical firms say they have beenforced to phase out certain medicine to stay in business.

"We aren't a charity. We have expenses and production costs,and if a company isn't making profit it will have to haltproduction," said Said Ibrahim, factory manager at EIPICO, oneof Egypt's largest pharmaceutical companies.

That brings no comfort to pharmacists and sick Egyptians.

Out of insulin for weeks, Ali Etman said he was recentlyforced to turn away eight diabetes patients from his Cairopharmacy in a single day.

"Patients who come looking for insulin ask me: 'What am Isupposed to do? Die?' and I don't know what to tell them. Idon't have the drugs they need," Etman said.

Egypt floated its currency on Nov. 3, abandoning a peg of8.8 pounds to the U.S. dollar and allowing the currency toroughly halve in value to about 17.50 on Tuesday.

The float helped the cash-strapped government clinch a $12billion IMF loan it hopes will unlock investment and revivegrowth that has been hampered by political uncertainty since the2011 uprising that toppled President Hosni Mubarak.

But the medicine shortages are piling pressure on thegovernment of general-turned-president Abdel Fattah al-Sisi, whohas been at pains to reassure a populace already strugglng withdouble-digit inflation and intermittent shortages that theywould be shielded from the worst effects of economic reforms.

Talk of a looming healthcare crisis has dominated popularevening chatshows, with doctors calling in nightly to reportrapidly depleting stocks and patients being turned away fromhospitals for lack of supplies.

The Health Ministry has blamed the problem on panickingEgyptians hoarding medicines and said it would not raise prices.

Drug shortages are not new to Egypt. More medicines hadalready begun disappearing from shelves early this year as asevere shortage of dollars in the banks meant pharmaceuticalfirms could not pay for the necessary imports.

Egypt has struggled to earn enough dollars since the 2011uprising scared off foreign investors and tourists and thecentral bank drained its reserves defending the currency peg.

The Health Ministry set up a Drug Shortages Directorate in2012 to minimise the impact by suggesting suitable substitutesfor missing medicines. But the situation has only worsened.

EIPICO's vice president told Reuters about 1,600 drugs hadgone short in recent months, including 35 that have noalternatives and would disappear from the market if price capswere not eased.

"Distributors are now telling pharmacies nothing imported isavailable. The problem has been going on for a while, but hasonly turned into a crisis in recent weeks," Etman said.

SITUATION WORSENING

Egypt's drugs market is 40 percent multinational - bigsuppliers include Pfizer, Novartis,GlaxoSmithKline and Sanofi - and 60 percentdomestic. Nearly all of it is in private hands, with annualsales worth a total of about 50 billion pounds before the float.

Ahmed al-Ezaby, head of the medicine industry division atFederation of Egyptian Industries, said Egypt imports about $600million in finished medicines per year and $1.8 billion inactive ingredients.

Officials at multinationals said they were concerned at theworsening situation. One industry source said companies were nowin talks with Egyptian ministries on the possibility ofrestoring some prices to pre-Nov. 3 levels, in dollar terms, toensure supplies of the most critical medicines.

The multinationals have local factories set up but 15-20percent of drugs are imported, while 80-85 percent are producedlocally. About 70 percent of all drugs in Egypt are generic anddomestic-made.

A spokesman for Sanofi said the French group was "activelyengaging local authorities to define a sustainable pricingmechanism".

Egypt's supply problems echo those in Venezuela, where alack of dollars has also created drug shortages and leftmanufacturers nursing big losses.

Before the flotation, Egypt faced a dollar shortage that sawimported goods ranging from electronic equipment to sugardisappear briefly from shelves in the past year.

The central bank rationed supplies via weekly auctions,earmarking the little it had for essential items like medicine.

Dollar supply is less of an issue since the flotation. Butthe cost of buying the greenback is because companies importactive ingredients they need to make generic medicines.

The government, which already raised prices on a slew ofmedicines this year, is under pressure to keep drugs affordablefor tens of millions of poor Egyptians.

It has blamed the crisis on hoarding and greed.

"It's an orchestrated crisis. The decision to float thepound was taken...and two hours later people began saying wehave a crisis and we don't have meds," Health Ministry spokesmanKhaled Mogahed told the Egyptian TV channel Mehwar.

"It's a way to push for a rise in medicine prices, whichwill not happen."

Mogahed did not respond to requests from Reuters forcomment.

The companies want the government to remove the price capsentirely or re-adjust them to ease their losses.

The Health Ministry met last week with drug industry leadersto discuss an emergency plan. It has offered to subsidisepharmaceutical companies to the tune of $165 million to supportimports of life-saving drugs that have no viable substitutes,including some cancer treatments.

Companies said the amount was not nearly enough whilerolling out a new subsidy programme would take time.

"There's no way of knowing how long this amount will lastbecause cancer drugs are expensive and it depends on theshortages, but the amount is not enough to solve the problem,"said Adel Abdel Maksoud, head of the pharmacy division at theCairo Chamber of Commerce.

TWITTER PHARMACY

In the meantime the companies say they have to stop offeringthe drugs which most cut into their profits. Some have alreadysent back shipments that were ordered before the float butarrived after, as selling them at the fixed prices would havecreated big losses. They all say they have to downsize and cutout certain drugs.

"We're working on a strategy to eliminate any product that'snot profitable. But companies that depend on unprofitableproducts will be forced to shut down now given the new currencyrate," said ITO Pharma's deputy general manager Mohamed Geoushy.

More life-saving drugs will soon disappear, he said.

His company is one of only two suppliers of cyclosporine, adrug used to prevent organ rejection during transplants. Itrecently stopped importing the drug, he said.

Pharmacists say patients have no choice but to resort to ablack market for once-common items like saline and glucose atprices often 10 times higher than the official caps and farbeyond the reach of most.

On Twitter, resourceful Egyptians have set up the hashtag"Twitter_Pharmacy" to swap medicines they cannot find in shops.Hospitals are using social media to advertise their needs.

"Every minister should have sat down with the governmentafter the float and discussed an emergency plan because it's acrisis if patients can't find life-saving medicines," said OsamaTahoon, general manager of medicine producer Julphar Egypt.

"We can give up sugar or tea, but we can't give upmedicine." (Additional reporting by Ben Hirschler in London, Editing byAngus MacSwan)

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.